GlassScriptPhysician profile
Nicholas B Cline
NPI 1801356985
$2,162.96
in general payments reported to CMS, 2019-2025
13 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $120 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.96 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $528.98 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $493.78 | 2024-2025 | Dupixent |
| Amgen INC. | $191.30 | 2025 | Tezspire |
| Genentech USA, INC. | $154.72 | 2025 | Xolair |
| Glaxosmithkline, LLC. | $138.58 | 2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $134.62 | 2025 | |
| Novartis Pharmaceuticals Corporation | $108.89 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $106.30 | 2025 | Neffy |
| Optinose US, INC. | $92.35 | 2025 | |
| Grifols USA, LLC | $84.15 | 2025 | Xembify |
| Csl Behring | $58.32 | 2025 | Andembry |
| Pfizer INC. | $36.04 | 2025 | |
| Pharming Healthcare, INC. | $34.93 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.